Earnings call transcript: Zepp Health shows strong Q1 2026 growth amid challenges

Zepp Health posted Q1 2026 revenue of $51.5 million, up 33.8% year over year, with gross margin improving to 37.7% and operating loss narrowing to $6.3 million. Growth was driven by new product launches including Active Max, Active 3 Premium, and T-Rex Ultra 2, while the stock rose 3.55% in aftermarket trading to $6.41. Management guided Q2 revenue to $63 million-$68 million and signaled more launches ahead, though higher memory costs, FX pressure, and continued losses remain risks.

Analysis

ZEPP’s print is less about one-quarter execution and more about evidence that the company has finally found a tighter product-market wedge: serious-training consumers are proving less price elastic than casual wearable buyers. The important second-order effect is that premium mix can outpace unit growth for several quarters because the brand is now using event-based validation (HYROX, marathon, trail) to raise willingness-to-pay before competitors can respond with feature parity.

The hidden upside is operating leverage if management is right that launch intensity normalizes after H1. A step-down in R&D/marketing into H2, layered on top of a higher ASP base, can mechanically widen margins faster than headline revenue growth suggests. That creates a path where ZEPP can look like a gross-margin expansion story rather than a pure top-line story, which matters because the equity has historically re-rated on evidence of sustainability, not just growth.

The main risk is that the current narrative is front-loaded: launches, partnerships, and channel spend all help near-term demand but also pull forward brand investment. If memory inflation persists into H2 while conversion from premium awareness to repeat purchase stalls, the market will quickly stop capitalizing the story as a turnaround and revert to treating ZEPP as a cash-burning hardware name. The balance sheet is not distressed today, but the cash burn profile means any miss in Q2/Q3 could force a sharper de-rating than the stock’s recent momentum implies.

Consensus is probably underestimating how much this pressures Garmin at the low-to-mid premium end rather than the ultra-premium end. ZEPP does not need to take share broadly; it just needs to keep trading users up the ladder in the $169-$549 bands, where feature differentiation is thinner and marketing-driven share shifts can happen faster than in legacy fitness categories. That makes the next two quarters the key proof window: if margins hold while launch cadence remains high, the stock can rerate; if not, the move likely unwinds quickly because expectations are now ahead of the cash-flow reality.

Key Decisions for Investors

• Long ZEPP into the next 2 earnings cycles, but size as a tactical momentum/turnaround position rather than a core hold; upside is a continued gross-margin re-rate if H2 expense normalization materializes, while downside is a fast multiple compression if launch spend persists without cash-flow inflection.
• Pair trade: long ZEPP / short GRMN over 3-6 months. Thesis is ZEPP has more operating leverage to premium mix expansion and more room for share gains at lower price tiers; risk is Garmin’s superior balance sheet and brand durability if ZEPP’s launch-driven demand proves temporary.
• Buy ZEPP call spreads on any post-rally consolidation, targeting the next 1-2 quarters. Best setup is a structure that benefits from a modest re-rating rather than assuming an outright squeeze, since the stock is still vulnerable to volatility and cash-burn headlines.
• Set a hard risk trigger: if Q2 shows no sequential operating expense normalization or if gross margin slips despite higher ASPs, reduce exposure aggressively. That would signal the story is still marketing-led rather than structurally better economics.
• For more conservative accounts, express the view via a small long ZEPP / short consumer-electronics basket rather than outright long stock. This isolates the premiumization and category-share thesis while dampening idiosyncratic execution risk.